Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
6(75.0%)
Phase 2
1(12.5%)
Phase 3
1(12.5%)
8Total
N/A(6)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT07424690Not ApplicableNot Yet Recruiting

Catheter Ablation vs Conservative Care in Elderly Patients With Atrial Fibrillation

Role: collaborator

NCT07008729Not ApplicableActive Not Recruiting

Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world Data

Role: collaborator

NCT06689111Not ApplicableRecruiting

Correlation of Typical LBBB Mechanical Activation Pattern by 2D Strain Echocardiography With Acute GWE Improvement in Patients Receiving LBBp or Conventional BiVp for Cardiac Resynchronization Therapy (Echo LBBp)

Role: collaborator

NCT06972082Not ApplicableRecruiting

Prevention and Treatment of AKI VEXUS Guided Post Cardiac Surgery

Role: lead

NCT06242171Active Not Recruiting

Prognostic Indices of Atheromatosis Severity and Coronary Artery Bypass Surgery Outcomes for Patients With Coronary Artery Disease

Role: lead

NCT03854149Completed

Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study

Role: collaborator

NCT03013270Not ApplicableCompleted

Aerobic, Resistance, Inspiratory Training Outcomes in Heart Failure

Role: lead

NCT04224675Not ApplicableUnknown

Captopril Versus Atenolol to Prevent Expansion Rate of Thoracic Aortic Aneurysms

Role: lead

NCT00247208Phase 3Completed

The SOS (Stenting Of Saphenous Vein Grafts) Trial

Role: collaborator

NCT00345501Phase 2Completed

Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

Role: lead

All 10 trials loaded